
Benign Prostatic Hyperplasia
Latest News
Latest Videos

Shorts










Podcasts
CME Content
More News

Urocross produced deepening IPSS improvement through 24 months post-retrieval, with Kevin T. McVary, MD, FACS, attributing a post-removal symptomatic boost to completed prostatic remodeling and full preservation of future treatment options.

Enucleation is appropriate for the vast majority of patients with BPH, but certain patient profiles—including prior radiation, significant neurologic conditions, morbid obesity, and dementia—warrant caution or referral to specialists, whereas the most consistent technical failure among surgeons past their learning curve is inadequate apical tissue removal driven by discomfort with sphincter proximity, according to Amy E. Krambeck, MD.

The prospective RELIEF study will evaluate the safety and preliminary efficacy of IRE delivered via the NanoKnife System for BPH-related symptoms.

Data from the BREEZE trial support the efficacy, safety, and tolerability of the Zenflow Prostatic Spring for BPH-related LUTS.

Kevin C. Zorn, MD, FRCSC, FACS, discusses the factors that clinicians should consider when selecting among different MIST options for BPH.

In this video, Nicole L. Miller, MD, FACS, discusses her approach to assessing patients after prior treatment failure for benign prostatic hyperplasia.

Bilal I. Chughtai, MD, highlights 12-month cystoscopic data from the pivotal IDE trial of the Zenflow Spring System.

Interim results from the pivotal Expander-2 showed sustained symptom improvement through 24 months with the Urocross Expander system for BPH.

These FAQs outline key AUA guideline recommendations on the medical and surgical management of LUTS secondary to BPH.

These FAQs outline key AUA guideline recommendations on the presentation and evaluation of LUTS secondary to BPH.

Advances in laser technology, morcellator design, and anesthetic approach have substantially improved HoLEP efficiency and patient recovery over the past decade, while surgeon-owned procedural checklists and pre-morcellation hemostasis remain the most critical safety practices for avoiding morcellator injury.

The first patients have been treated in WOLVERINE, a prospective feasibility trial of the Edison Histotripsy System for BPH.

Clearance of the non-permanent implant technology is backed by safety and efficacy results from the pivotal Expander-2 trial.

At 1 year, patients randomized to Rezūm showed a 4.6-point greater improvement on the IPSS symptom score compared with those escalated to combination therapy.

Pivotal trial of Butterfly Medical device for BPH reaches final completion
The results from this study are expected to support an application to the FDA for premarket approval of the Butterfly device.



















